Nov.
17
HomeNews Details

Innovative drug R&D company "CataX AI" has completed a seed round financing of 40 million yuan.

2026-11-17 12:02
Recently, Shanghai CataX AI Biomedical Technology Co., Ltd. (referred to as "CataX AI") announced that it has completed a RMB 40 million seed round of financing, which was incubated and exclusively invested by Qiming Venture Partners. It is understood that CataX AI, founded in Shanghai, is an Agent-native innovative drug R&D company. CataX AI focuses on the clinical development end, takes Agent as the technical base, and thus builds a brand-new organizational paradigm named "Clinical-of-One" (full-stack clinical). It plans to promote preclinical and early clinical stage assets to complete the Proof of Concept (PoC) through in-licensing or co-development.